InVenis Biotherapies - About the company
InVenis Biotherapies is an unfunded company based in France, founded in 2021. It operates as a Developer of regenerative therapies based on blood platelet for neurodegenerative diseases. InVenis Biotherapies has not raised any funding yet. The company has 466 active competitors, including 164 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.
Key Metrics
Sign up to download InVenis Biotherapies' company profile
InVenis Biotherapies's funding and investors
InVenis Biotherapies has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
InVenis Biotherapies's Competitors and alternates
Top competitors of InVenis Biotherapies include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of InVenis Biotherapies, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 71/100 | |
3rd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 65/100 | |
6th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
7th | Alchemab 2019, London (United Kingdom), Series A | Developer of antibody therapeutics for treating oncology and neurodegenerative conditions | $149M | 65/100 | |
8th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Developer of small molecule inhibitors targeting specific disease associated enzymes | $192M | 64/100 | |
9th |  D&D Pharmatech 2014, Seongnam-si (South Korea), Public | Developer of GLP-1-based therapeutics for metabolic disease treatment | $205M | 64/100 | |
10th | US World Meds 2001, Louisville (United States), Series B | Developer of therapeutics for the treatment of multiple diseases | $149M | 63/100 | |
508th |  InVenis Biotherapies 2021, France, Unfunded | Developer of regenerative therapies based on blood platelet for neurodegenerative diseases | - | - | 16/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on InVenis Biotherapies's competitors? Click here to see the top ones
InVenis Biotherapies's Investments and acquisitions
InVenis Biotherapies has made no investments or acquisitions yet.
Reports related to InVenis Biotherapies
Here is the latest report on InVenis Biotherapies's sector:
Are you a Founder ?
FAQs about InVenis Biotherapies
Explore our recently published companies
- Duo - Seattle based, Unfunded company
- Studio - New York based, 2019 founded, Unfunded company
- Dr.-Ing. Prehn - Germany based, 2021 founded, Unfunded company
- Ovo Design - Unfunded company
- Joe Witness - Langley based, Unfunded company
- Adfeedbins - United Kingdom based, Unfunded company
